PALVELLA THERAPEUTICS, INC. financial data

Symbol
PVLA on Nasdaq
Location
Wayne, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 753% %
Debt-to-equity 51% %
Return On Assets -43% % -135%
Operating Margin 270% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,836,490 shares 797%
Common Stock, Shares, Outstanding 11,088,329 shares 740%
Entity Public Float $9,200,000 USD -18%
Common Stock, Value, Issued $11,000 USD 1000%
Weighted Average Number of Shares Outstanding, Basic 11,064,282 shares 525%
Weighted Average Number of Shares Outstanding, Diluted 11,064,282 shares 525%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,352,000 USD -97%
Research and Development Expense $18,263,000 USD 105%
General and Administrative Expense $13,401,000 USD 94%
Operating Income (Loss) $31,664,000 USD -966%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $32,952,000 USD -67%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $32,918,000 USD -231%
Earnings Per Share, Basic -2 USD/shares -119%
Earnings Per Share, Diluted -2 USD/shares 74%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $63,567,000 USD 228%
Cash, Cash Equivalents, and Short-term Investments $19,400,000 USD -57%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD -100%
Assets, Current $66,937,000 USD
Assets $66,937,000 USD 226%
Accounts Payable, Current $3,481,000 USD 335%
Employee-related Liabilities, Current $1,247,000 USD -46%
Liabilities, Current $10,312,000 USD 142%
Liabilities $28,255,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $104,000 USD
Retained Earnings (Accumulated Deficit) $122,736,000 USD 62%
Stockholders' Equity Attributable to Parent $38,682,000 USD
Liabilities and Equity $66,937,000 USD 226%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,768,000 USD -514%
Net Cash Provided by (Used in) Financing Activities $1,202,000 USD
Net Cash Provided by (Used in) Investing Activities $9,000,000 USD -24%
Common Stock, Shares Authorized 200,000,000 shares 5233%
Common Stock, Shares, Issued 11,088,329 shares 740%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,976,000 USD -624%
Deferred Tax Assets, Valuation Allowance $93,254,000 USD 482%
Deferred Tax Assets, Gross $93,254,000 USD 482%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $32,266,000 USD -235%
Deferred Tax Assets, Operating Loss Carryforwards $81,971,000 USD 793%
Preferred Stock, Shares Issued 15,617 shares -0.01%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $700,000 USD -68%
Additional Paid in Capital $161,303,000 USD -53%
Preferred Stock, Shares Outstanding 15,617 shares -0.01%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $4,585,000 USD 799%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%